Chest Diseases Department, Izmir Katip Celebi University Atatürk Research and Training Hospital, İzmir, Turkey.
Chest Diseases Department, Yedikule Hospital for Chest Disease and Thoracic Surgery, Istanbul, Turkey.
Expert Rev Respir Med. 2021 Aug;15(8):1069-1076. doi: 10.1080/17476348.2021.1923484. Epub 2021 May 13.
Although COPD is not one of the most common comorbidities in COVID-19 patients, it can be more fatal in this group. This study aimed to investigate the characteristics and prognosis of COPD patients among the population with COVID-19.
Patients diagnosed with positive PCR test were included in our multicentered, retrospective study. Patients with airway obstruction (previous spirometry) were included in 'COPD group'.
The prevalence of COPD in COVID-19 patients was 4.96%(53/1069). There was a significant difference between COPD and non-COPD COVID-19 patients in terms of gender, mean age, presence of dyspnea, tachypnea, tachycardia, hypoxemia and presence of pneumonia. The mortality rate was 13.2% in COPD, 7% in non-COPD patients(p = 0.092). The significant predictors of mortality were higher age, lymphopenia (p < 0.001), hypoxemia (p = 0.028), high D-dimer level (p = 0.011), and presence of pneumonia (p = 0.043) in COVID-19 patients.
Our research is one of the first studies investigating characteristics of COPD patients with COVID-19 in Turkey. Although COPD patients had some poor prognostic features, there was no statistical difference between overall survival rates of two groups. Age, status of oxygenization, serum D-dimer level, lymphocyte count and pneumonia were significantly associated parameters with mortality in COVID-19.
虽然 COPD 不是 COVID-19 患者中最常见的合并症之一,但在该人群中它可能更致命。本研究旨在调查 COVID-19 患者中 COPD 患者的特征和预后。
将被诊断为 PCR 检测阳性的患者纳入我们的多中心回顾性研究。有气道阻塞(既往肺功能检查)的患者被纳入“COPD 组”。
COVID-19 患者中 COPD 的患病率为 4.96%(53/1069)。COPD 和非 COPD COVID-19 患者在性别、平均年龄、呼吸困难、呼吸急促、心动过速、低氧血症和肺炎存在方面存在显著差异。COPD 组的死亡率为 13.2%,非 COPD 组为 7%(p=0.092)。COVID-19 患者死亡的显著预测因素是年龄较大、淋巴细胞减少(p<0.001)、低氧血症(p=0.028)、高 D-二聚体水平(p=0.011)和肺炎存在(p=0.043)。
我们的研究是土耳其首次研究 COVID-19 合并 COPD 患者特征的研究之一。尽管 COPD 患者存在一些预后不良的特征,但两组的总生存率无统计学差异。年龄、氧合状态、血清 D-二聚体水平、淋巴细胞计数和肺炎是 COVID-19 患者死亡的显著相关参数。